Dystonia Canada News

March 29, 2018

In recent months, DMRF Canada has received an increasing number of inquiries from dystonia patients about the efficacy of medical marijuana for the treatment of dystonia and other movement disorders. The research in this area is still inconclusive, with more studies on the way. Our Spring 2018 Newsletter included an article about what we now so far.  Please find a list of sources below:

Read more...
March 27, 2018

"We are very excited to serve as the home of the first Clinical Fellowship for Movement Disorders supported by Allergan Canada. The committee couldn't have selected a better candidate than Dr. Lizarraga, a bright, enthusiastic, inquisitive and dedicated young movement disorders trainee who will definitely make the most of this support and will make the Canadian dystonia community proud." - Dr. Anthony Lang, Toronto Western Hospital 

Read more...
March 5, 2018
This past month, members of the the DMRF Medical and Scientific Advisory Committee (MSAC) representing key opinion leaders in movement disorders, neuroscience and related fields met in Texas to offer their guidance on future research directions and priorities. Read more...
March 1, 2018

As a proud member of Neurological Health Charities Canada (NHCC), DMRF Canada is pleased to present an opinion piece in the Globe and Mail that speaks to the urgent need for additional research funding and more supports provided to individuals dealing with neurological conditions in Canada. Read the article here.

Read more...
February 27, 2018

Cervical dystonia is a focal dystonia that affects the head and neck. Cervical dystonia produces excessive muscle contractions in the neck. These muscle contractions cause involuntary, repetitive movements and awkward positions of the head, neck, and sometimes shoulders.

Cervical dystonia is sometimes referred to as spasmodic torticollis.

Cervical dystonia may cause:

Read more...
February 26, 2018

The Dystonia Medical Research Foundation (DMRF) Canada, in partnership with Allergan Canada, is pleased to announce the selection of the candidate for the first-ever Clinical Fellowship for Movement Disorders, with a specialty in dystonia.  Please click here to learn more.

Read more...
February 26, 2018

Details of the study and eligibility details are available here. Canadian patients are welcome to participate in the study if eligible. The exception for international participants is that while some travel expenses are covered once participants have been enrolled in the study, only certain expenses within the United States can be covered. 

Read more...
February 4, 2018

Approval is based on the first large-scale neurotoxin trial to demonstrate meaningful functional improvement in pediatric lower limb spasticity

The Ipsen Biopharmaceuticals Canada Inc., the Canadian affiliate of Ipsen (EURONEXT PARIS: IPN) (ADR: IPSEY) today announced that Health Canada has approved DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients two years of age and older.

Click here for the press release. 

Read more...
February 4, 2018

What is Chucks Run, Walk and Wheel for Dystonia?

The Chuck’s Run, Walk and Wheel 5KM for dystonia is a fun, family-friendly event, hosted at High Park, Toronto on Sunday, June 3, 2018 to raise awareness and funds for dystonia, a neurological movement disorder.

Registration: $39 or you can fundraise $150 and waive your registration fee.

Read more...
January 24, 2018

Novel sophisticated research tools are providing investigators new ways to explore the genetics of dystonia. Researchers have the ability to quickly sequence individual genes, analyze whole genomes, and analyze gene expression patterns. Individuals and families who volunteer for genetic studies contribute invaluably to research progress.

Read more...